• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lialda (Mesalamine) Delayed-release Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

December 2013

Summary View

ADVERSE REACTIONS

Post marketing Experience
  • anaphylactic reaction, Steven-Johnson syndrome (SJS), and drug reaction with eosinophilia and systematic symptoms (DRESS)
     

 

August 2013

Summary View

 

WARNINGS AND PRECAUTIONS

  • Interference with Laboratory Tests - Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and mesalamine’s main metabolite, N-acetylaminosalicylic acid (N-Ac-5-ASA). An alternative, selective assay for normetanephrine should be considered.